A retrospective study examined semaglutide use around elective lipoabdominoplasty (n = 80)[1]. Our overview of GLP-1 use before surgery covers the broader perioperative guidance. This study measured complications during the 30 days after one specific operation.
What did the researchers observe?
Complications affected 45% of patients who continued semaglutide until surgery and 30% of those who stopped two weeks earlier. The rate was 10% in both the four-week group and the group that had never taken semaglutide [1]. Recorded problems included wound separation, infection and fluid buildup. No patients were readmitted or had another operation.
Can the study establish a stop date?
The researchers matched patients on age, body mass index and surgical technique. They did not randomly assign when patients stopped treatment. Other differences could account for some of the observed gap. Tell your surgery and anesthesia team which medication you take, your dose and when you last took it.